Intention of reverse stock split

The board of directors and CEO/CFO Anders Fink Vadsholt has today entered into a severance agreement pursuant to which Mr. Vadsholt will step down as CEO/CFO of the Company.

Change in management

Major shareholder announcement

May 19, 2023

Orphazyme A/S (ORPHA.CO) (the “Company”), hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Scandinavian Investment Group A/S, that as of May 16, 2023, Scandinavian Investment Group A/S holds shares corresponding to 10.00% of the total share capital and voting rights in the Company.

Major shareholder announcement

Major shareholder announcement

May 17, 2023

Orphazyme A/S (ORPHA.CO) (the “Company”), hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from MH Investment ApS, that as of May 16, 2023, MH Investment ApS holds shares corresponding to 10.00% of the total share capital and voting rights in the Company.

Major shareholder announcement

Resolutions passed at the Annual General Meeting

May 17, 2023

Copenhagen, Denmark, May 17, 2023 – Orphazyme A/S (ORPHA.CO) (the “Company”), today held its Annual General Meeting, at which the Annual General Meeting.

Company announcement Resolutions passed at the Annual General Meeting

New members of the Board of Directors of Orphazyme

Changes to the Board of Directors

May 17, 2023

Orphazyme A/S (ORPHA.CO) (the “Company”), hereby announces that during the Annual General Meeting on May 17, 2023, Bo Jesper Hansen, John Sommer Schmidt and Anders Fink Vadsholt withdrew their candidacy as members of the Board of Directors.

Company announcement Change to Board of Directors

Selskabsmeddelelser